• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice.假病毒 rVSVΔG-ZEBOV-GP 感染视网膜和中枢神经系统中的神经元,导致新生小鼠发生细胞凋亡和神经退行性病变。
Cell Rep. 2019 Feb 12;26(7):1718-1726.e4. doi: 10.1016/j.celrep.2019.01.069.
2
Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP).接种基于重组水疱性口炎病毒的埃博拉疫苗(rVSVΔG-ZEBOV-GP)后对扎伊尔埃博拉糖蛋白和病毒载体蛋白的细胞和体液免疫。
Vaccine. 2023 Feb 17;41(8):1513-1523. doi: 10.1016/j.vaccine.2023.01.059. Epub 2023 Jan 31.
3
Characterization of rVSVΔG-ZEBOV-GP glycoproteins using automated capillary western blotting.采用自动化毛细管 Western 印迹技术对 rVSVΔG-ZEBOV-GP 糖蛋白进行表征。
Vaccine. 2020 Oct 21;38(45):7166-7174. doi: 10.1016/j.vaccine.2020.08.001. Epub 2020 Sep 18.
4
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.rVSVΔG-ZEBOV-GP 埃博拉疫苗(ERVEBO®)接种 1 或 2 剂后的免疫原性和疫苗脱落:在儿童和成人中进行的一项 2 期、随机、安慰剂对照试验的结果。
Clin Infect Dis. 2024 Apr 10;78(4):870-879. doi: 10.1093/cid/ciad693.
5
rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model.rVSVΔG-ZEBOV-GP疫苗在非人灵长类埃博拉病毒攻击模型中的广泛剂量范围内具有高度免疫原性且有效。
Viruses. 2025 Feb 28;17(3):341. doi: 10.3390/v17030341.
6
Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.rVSVΔG-ZEBOV-GP 疫苗的免疫原性、批次一致性和安全性延长:健康成年人中进行的 3 期随机、双盲、安慰剂对照研究。
J Infect Dis. 2019 Aug 30;220(7):1127-1135. doi: 10.1093/infdis/jiz241.
7
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.rVSVΔG-ZEBOV-GP(也称为V920),用埃博拉扎伊尔糖蛋白假型化的重组水疱性口炎病毒:风险/效益评估关键考量的标准化模板
Vaccine X. 2019 Jan 29;1:100009. doi: 10.1016/j.jvacx.2019.100009. eCollection 2019 Apr 11.
8
Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease.用于埃博拉病毒病的基因工程减毒活疫苗rVSVΔG-ZEBOV-GP的环境风险评估
Vaccines (Basel). 2020 Dec 19;8(4):779. doi: 10.3390/vaccines8040779.
9
Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon.在撒哈拉以南非洲儿科人群中,载体埃博拉疫苗 rVSV-ΔG-ZEBOV-GP 的复制、安全性和免疫原性:在加蓬兰巴雷内居住的 1-12 岁儿童中进行的一项随机对照、开放性标签试验。
J Infect. 2024 Oct;89(4):106237. doi: 10.1016/j.jinf.2024.106237. Epub 2024 Aug 8.
10
Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.rVSVΔG-ZEBOV-GP 埃博拉疫苗(ERVEBO®)在非洲临床试验参与者中的免疫原性按年龄、性别和基线 GP-ELISA 滴度划分:三项 2/3 期试验的事后分析。
Vaccine. 2022 Nov 2;40(46):6599-6606. doi: 10.1016/j.vaccine.2022.09.037. Epub 2022 Oct 5.

引用本文的文献

1
Ophthalmological manifestations and plasma markers of inflammation in Ebola survivors in post-treatment era.埃博拉幸存者治疗后时代的眼科表现及炎症血浆标志物
Sci Rep. 2025 Apr 29;15(1):14966. doi: 10.1038/s41598-025-96256-4.
2
CpG oligodeoxynucleotides and pan-serotype inhibitors control neurotropic dengue infection in novel immune competent neonatal mouse model.CpG 寡脱氧核苷酸和泛血清型抑制剂在新型免疫健全新生小鼠模型中控制嗜神经性登革热感染。
Emerg Microbes Infect. 2025 Dec;14(1):2477668. doi: 10.1080/22221751.2025.2477668. Epub 2025 Jul 16.
3
Safety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland Bandavirus.一种重组水疱性口炎病毒载体疫苗针对严重发热伴血小板减少综合征病毒和哈特兰病毒的安全性、免疫原性及有效性
Vaccines (Basel). 2024 Dec 12;12(12):1403. doi: 10.3390/vaccines12121403.
4
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.新发和再发传染病:全球趋势及预防和控制新策略。
Signal Transduct Target Ther. 2024 Sep 11;9(1):223. doi: 10.1038/s41392-024-01917-x.
5
Proposing a Neurotropic Etiology for Acute Posterior Multifocal Placoid Pigment Epitheliopathy and Relentless Placoid Chorioretinitis.提出急性后极部多灶性扁平色素上皮病变及顽固性扁平脉络膜视网膜病变的嗜神经病因学。
Front Ophthalmol (Lausanne). 2022 Jan 10;1:802962. doi: 10.3389/fopht.2021.802962. eCollection 2021.
6
Establishment and application of a surrogate model for human Ebola virus disease in BSL-2 laboratory.建立和应用在二级生物安全实验室中人类埃博拉病毒病的替代模型。
Virol Sin. 2024 Jun;39(3):434-446. doi: 10.1016/j.virs.2024.03.010. Epub 2024 Mar 29.
7
A lethal mice model of recombinant vesicular stomatitis viruses for EBOV-targeting prophylactic vaccines evaluation.用于埃博拉病毒靶向预防性疫苗评估的重组水疱性口炎病毒致死性小鼠模型。
Virol Sin. 2024 Jun;39(3):516-519. doi: 10.1016/j.virs.2024.03.008. Epub 2024 Mar 24.
8
YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge.携带黄热病毒17D株的埃博拉疫苗候选物可保护小鼠免受致死性替代埃博拉病毒和黄热病毒攻击。
NPJ Vaccines. 2023 Jul 11;8(1):99. doi: 10.1038/s41541-023-00699-7.
9
Ebola virus disrupts the inner blood-retinal barrier by induction of vascular endothelial growth factor in pericytes.埃博拉病毒通过诱导周细胞中的血管内皮生长因子破坏血视网膜内屏障。
PLoS Pathog. 2023 Jan 18;19(1):e1011077. doi: 10.1371/journal.ppat.1011077. eCollection 2023 Jan.
10
BSL2-compliant lethal mouse model of SARS-CoV-2 and variants of concern to evaluate therapeutics targeting the Spike protein.BSL2 级相容的 SARS-CoV-2 致死性小鼠模型及其关注变异株,用于评估针对 Spike 蛋白的治疗药物。
Front Immunol. 2022 Jul 28;13:919815. doi: 10.3389/fimmu.2022.919815. eCollection 2022.

假病毒 rVSVΔG-ZEBOV-GP 感染视网膜和中枢神经系统中的神经元,导致新生小鼠发生细胞凋亡和神经退行性病变。

Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice.

机构信息

Division of Biotechnology Review and Research-III, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.

Laboratory of Immunology, National Eye Institute, NIH, Bethesda, MD 20892, USA.

出版信息

Cell Rep. 2019 Feb 12;26(7):1718-1726.e4. doi: 10.1016/j.celrep.2019.01.069.

DOI:10.1016/j.celrep.2019.01.069
PMID:30759384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6748882/
Abstract

Zaire Ebola virus (ZEBOV) survivors experience visual and CNS sequelae that suggests the ZEBOV glycoprotein can mediate neurotropism. Replication-competent rVSVΔG-ZEBOV-GP vaccine candidate is generally well tolerated; however, its potential neurotropism requires careful study. Here, we show that a single inoculation of rVSVΔG-ZEBOV-GP virus in neonatal C57BL/6 mice results in transient viremia, neurological symptoms, high viral titers in eyes and brains, and death. rVSVΔG-ZEBOV-GP infects the inner layers of the retina, causing severe retinitis. In the cerebellum, rVSVΔG-ZEBOV-GP infects neurons in the granular and Purkinje layers, resulting in progressive foci of apoptosis and neurodegeneration. The susceptibility to infection is not due to impaired type I IFN responses, although MDA5, IFNβ, and IFNAR1 mice have accelerated mortality. However, boosting interferon levels by co-administering poly(I:C) reduces viral titers in CNS and improves survival. Although these data should not be directly extrapolated to humans, they challenge the hypothesis that VSV-based vaccines are non-neurotropic.

摘要

扎伊尔埃博拉病毒(ZEBOV)幸存者会出现视觉和中枢神经系统后遗症,这表明 ZEBOV 糖蛋白可能介导嗜神经性。复制型 rVSVΔG-ZEBOV-GP 疫苗候选物通常具有良好的耐受性;然而,其潜在的嗜神经性需要仔细研究。在这里,我们表明,在新生 C57BL/6 小鼠中单次接种 rVSVΔG-ZEBOV-GP 病毒会导致短暂的病毒血症、神经症状、眼睛和大脑中的高病毒滴度以及死亡。rVSVΔG-ZEBOV-GP 感染视网膜内层,导致严重的视网膜炎。在小脑,rVSVΔG-ZEBOV-GP 感染颗粒层和浦肯野细胞层的神经元,导致进行性凋亡和神经退行性变焦点。感染的易感性不是由于 I 型 IFN 反应受损所致,尽管 MDA5、IFNβ 和 IFNAR1 小鼠的死亡率加快。然而,通过联合施用 poly(I:C) 来提高干扰素水平可降低中枢神经系统中的病毒滴度并提高存活率。尽管这些数据不应直接外推至人类,但它们挑战了基于 VSV 的疫苗无嗜神经性的假设。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b4/6748882/6de2946ac624/nihms-1050329-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b4/6748882/24c6db15b254/nihms-1050329-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b4/6748882/c2eed1ebce67/nihms-1050329-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b4/6748882/87b63f433acc/nihms-1050329-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b4/6748882/6de2946ac624/nihms-1050329-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b4/6748882/24c6db15b254/nihms-1050329-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b4/6748882/c2eed1ebce67/nihms-1050329-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b4/6748882/87b63f433acc/nihms-1050329-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53b4/6748882/6de2946ac624/nihms-1050329-f0005.jpg